Our Expertise
A proven track record in search and evaluation, acquisition of new assets and out-licence of developed medicines
Our Expertise
A proven track record in search and evaluation, acquisition of new assets and out-licence of developed medicines
Meet Our Team
World renowned leadership and experience
Executive Chairman & Founder
Non-Executive Director
Non-Executive Director
Non-Executive Director
Chief Financial Officer
Global Head of Drug Development and Chief Medical Officer
Tobi is responsible for the clinical development of the drugs in Ellipses’ pipeline. He leads clinical strategy, coordinates the drug development teams to deliver the clinical programmes and is an ambassador for our Scientific Affairs Group.
Over the course of his career, Tobi has worked on over 300 early-stage clinical trials, with several of these trials providing the compounds that have gone on to become the new standard of care.
A Medical Oncologist by training, Tobi is a practicing clinician having begun his early career as an oncologist in Bremen, Germany and then at the Royal Marsden Hospital in London, before becoming a team leader in Clinical Drug Development at the University of New South Wales, Australia. He has
spent over a decade as a Professor at University College London, and most recently was the Executive Medical Director at the Sarah Cannon Research Institute. He holds a PhD from the Medical School of Hanover.
Chief Financial Officer
David has been Chief Financial Officer at Ellipses since its early stages and is also a Director on its Board.
As a central member of the executive team, he drives the company’s growth and helps to set its strategy, as well as taking on key responsibilities in funding and business development.
David has extensive experience as a CFO within the life sciences industry. He began his career at PricewaterhouseCoopers where he qualified as a chartered accountant, before holding CFO and Group Financial Controller positions at several life sciences companies. A personal highlight was his steering of Biotie Therapies through its listing on NASDAQ, as its CFO. More recently, he has served on the board of AIM-listed Alliance Pharmaceuticals, including currently as its Non-Executive Chairman.
David holds a degree in Chemistry from the University of Oxford.
Chief Development Officer, Non Clinical
Martin is an expert in drug development and manufacturing and has played a pivotal role in bringing thirteen drugs to market to date. His broad experience across the pharmaceutical industry started within big pharma at Aventis, includes eight years at Shire Pharmaceuticals, where he was a Senior Director of Product Development, and more recently as Global Head of Product Development and Manufacturing at HUYA Bioscience.
At Ellipses, Martin leads the non-clinical and preclinical development arms of the organisation, working in conjunction with the clinical development arm to progress Ellipses’ exciting portfolio of oncology assets.
Martin graduated with a degree in Applied and Analytical Chemistry from Staffordshire University and has a post-graduate certificate in management studies.
Head of Business Development & Licensing
Nicky has 15 years’ deal experience in the life-sciences and pharmaceutical industry with companies including GlaxoSmithKline, Speciality Pharma and GE Healthcare Life Sciences. At Ellipses, Nicky is responsible for in-licensing new assets to the company’s development pipeline, as well as their subsequent out-licensing.
Nicky has led multiple transactions including company and product acquisitions, and product divestments across all phases of drug development.
Nicky has a biochemistry degree and a PhD in drug delivery from University College London.
Head of Organisational Culture and Experience
Suzanne is responsible for driving the Ellipses company ethos, culture and enriching the work experience of the team. She joined Ellipses early in its inception and has worked to create a pioneering and entrepreneurial culture in which employees can achieve and thrive, alongside the focused hiring of talent to spur Ellipses forward in its mission of developing cancer drugs at pace.
Previously, Suzanne was HR Director (UK) and Director of Organisational Development, Europe, at Pfizer and HR and Communications Director at Basilea Pharmaceutica. She has served as a as a non-executive director at the Royal Surrey NHS Foundation Trust, where she was part of the team that drove its transition to Foundation Trust status. She holds a degree in Medieval, Modern and American History from the University of Hull.
Our Scientific Affairs Group
The largest oncology-focused network of key opinion leaders providing high-quality, independent and unbiased expertise
In memoriam
Professor Gordon McVie – An Oncology Pioneer
In every sense, Gordon McVie was a man of great stature. His outstanding achievements in cancer research and treatment were in keeping with his towering physical presence. Those of us who knew him, and worked alongside him, were constantly in awe of his boundless enthusiasm.
From the research lab to the rugby stadium, this genial Scotsman was always the same; making the most of every moment with the tremendous verve he showed throughout his distinguished life. His sudden and untimely death, has deprived us all of his perpetual drive to develop new treatments and make a difference to every patient with cancer.
As the founding chair of the Ellipses Scientific Affairs Group, he brought together and established the purpose for the world’s largest cancer-focused key opinion leader group, tasked with providing independent expertise and validating the science behind the most promising scientific discoveries. This ground-breaking work, coupled with the wisdom he brought to our board and executive team, played an enormous part in establishing Ellipses as an innovative accelerator of cancer drug development.
We owe Gordon a great debt of gratitude. His passion for giving cancer patients the best possible way ahead will continue to fuel our mission and vision, remaining engrained in the ethos of Ellipses.
[signatures]